Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Flovent HFA approved

Executive Summary

GlaxoSmithKline's CFC-free version of Flovent (fluticasone) for the treatment of asthma as prophylactic therapy in adults and adolescents 12 years and older clears FDA May 14. The drug is the second HFA nasal steroid to be approved after Aventis' Nasacort HFA inhaler for allergic rhinitis was cleared in April (1"The Pink Sheet" April 12, 2004, In Brief). A proposed rule on CFC-containing products is near publication (2"The Pink Sheet" April 26, 2004, In Brief)...

You may also be interested in...



Aventis Nasacort HFA approved

FDA clears Aventis'Nasacort HFA (triamcinolone acetonide) April 7 for nasal symptoms of seasonal and perennial allergic rhinitis for patients six years old and older. The drug is the first FDA-approved HFA nasal steroid; Aventis markets Nasacort AQ, the aqueous solution of triamcinolone, in a non-CFC metered-dose pump spray...

GeNeuro To Tackle Long COVID By Targeting Ancestor Viral Gene Activation

Switzerland’s GeNeuro will study whether its monoclonal antibody temelimab can prevent long-COVID, after data for the first time linked activation of human endogenous retroviruses (HERVs) to the condition and its associated neurological symptoms.

Executives On The Move: CFO Promoted At Novavax, Gilead Gets New Executive Vice President Of Research

Alpha Cognition, F2G and Immune Pharmaceuticals pick up new CEOs, and there is a new chief medical officer at Gemini Therapeutics.

UsernamePublicRestriction

Register

PS043974

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel